Default company panoramic image


Protein semi-synthesis for the next generation of novel, safer and more effective biological drugs.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Princeton, NJ, USA
  • Currency USD
  • Founded November 2012
  • Employees 1

Company Summary

ProteoDesign enables biotech companies to develop better biological drugs thanks to our patented and in vivo validated technology. Protein-based drugs are the most promising medicines but most of the $8Bn annual investment in R&D is wasted due to limitations in current technologies. We eliminate some key limitations (need to introduce mutations on the Ab and to re-engineer the cell production line) and we open up new therapeutic opportunities.


  • Default avatar
    Tom Muir

    Tom is a renowned world-leader on protein semi-synthesis and chemical biology, co-led the invention of SEPL, and consults for a variety of biotechnological companies. Prof. Muir received Ph.D. in organic chemistry in 1993, from the University of Edinburgh and was named associate professor in 2000, professor in 2002 and Richard E. Salomon Family Professor in 2005 at The Rockefeller University. In 2011 he moved to Princeton University where he is

  • Default avatar
    Miquel Vila-Perelló

    Miquel brings scientific knowledge and experience managing scientific teams: has made important contributions in the field of protein semi-synthesis, including the co-invention of Streamlined Expressed Protein Ligation and manages the Protein Center in the Chemistry Department at Princeton University. Dr. Vila-Perello received his PhD in chemistry in 2005 from the University of Barcelona (among the top European universities).

  • Default avatar
    Silvia Frutos

    Silvia brings deep scientific expertise and an intimate knowledge of European bioclusters: she is a member of the BioemprenedorXXI program, she joined the laboratory of Prof. Muir at the Rockefeller as a postdoc in 2007 and since 2011 works as a senior researcher at the biophysics research group in Barcelona (Spain). She received her PhD in chemistry in 2006 from the University of Barcelona (among the top European universities).

  • Default avatar
    Marc Montserrat

    Marc brings entrepreneurial, management and industry expertise: he has launched over 30 products, managed an international team responsible for a pharmaceutical portfolio with over $150M in annual revenues. He holds a M. of Engineering from the Universitat Politecnica de Catalunya (among the top European universities) and an MBA in Health Care Management from The Wharton School (University of Pennsylvania).